Bioinformatics, Convergence Science, and Systems Biology最新文献

筛选
英文 中文
Abstract 2483: An integrated bioinformatics pipeline for profiling cancer-immune interaction from whole exome sequencing of pembrolizumab clinical samples 2483:通过pembrolizumab临床样本的全外显子组测序来分析癌症免疫相互作用的集成生物信息学管道
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-2483
Xiaoqiao Liu, Xinwei Sher, Hongchao Lu, J. Zhuang, Weilong Zhao, Andrew Albright, Cinthia Umemoto, Christen Wudarski, M. Lane, M. Ayers, A. Webber, Sandra C. Souza, P. Qiu, D. Levitan, Jennifer Cho, D. Aurora-Garg, M. Marton, A. Snyder, Michael P. Morrissey, A. Loboda, Ronghua Chen, R. Cristescu
{"title":"Abstract 2483: An integrated bioinformatics pipeline for profiling cancer-immune interaction from whole exome sequencing of pembrolizumab clinical samples","authors":"Xiaoqiao Liu, Xinwei Sher, Hongchao Lu, J. Zhuang, Weilong Zhao, Andrew Albright, Cinthia Umemoto, Christen Wudarski, M. Lane, M. Ayers, A. Webber, Sandra C. Souza, P. Qiu, D. Levitan, Jennifer Cho, D. Aurora-Garg, M. Marton, A. Snyder, Michael P. Morrissey, A. Loboda, Ronghua Chen, R. Cristescu","doi":"10.1158/1538-7445.AM2019-2483","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-2483","url":null,"abstract":"Purpose We built an integrated analytic pipeline to robustly and comprehensively profile molecular features of pembrolizumab-treated tumors using whole exome sequencing (WES) data from clinical trials across different indications. Experimental design We implemented a computational framework for analysis of WES data generated by different sequencing vendors for 1467 samples from 8 major tumor types. Reads were first processed by BWA-MEM, Picard, and GATK (v2) to generate analysis-ready BAM files. Quality controls (QC) before downstream analysis included Y/X reads ratio for matched normal sample as patient sex prediction and tumor/normal concordance and contamination estimation by Conpair. Key molecular features were evaluated, including tumor mutation burden (TMB) by MuTect (v1) and VEP; HLA-I typing by OptiType; neoantigen burden by NetMHC (v3.4); mutation signature by deconstructSigs; allele-specific copy number by VarScan2 and Sequenza; clonality by PyClone; presence of oncogenic viruses (eg, EBV, HBV, HPV); and LOH score indicating homologous recombination deficiency (HRD-LOH). Results Concordance rate between predicted and clinical sex was 1446/1464 (98.8%), and 1420/1467 (96.8%) samples passed tumor-normal alignment QC. Highest TMB (median [range]) was detected in melanoma (245 [2-6246]) and urothelial carcinoma (UC) (124 [4-1579]), with lowest TMB in metastatic castration-resistant prostate cancer (52 [1-6143]) and ovarian cancer (OvCa) (49.5 [8-272]). The correlation of median TMB across 7 cancer types in our data and TCGA was Spearman R = 0.957. Within indications, there was no difference in TMB distribution for sequencing data originating from different sequencing vendors and TCGA data, which demonstrated concordance across data sets and robust TMB calling by our integrated pipeline. Neoantigen burden strongly correlated with TMB (N = 1420; Spearman R = 0.890). HPV was detected in 20/129 (15.5%) head and neck squamous cell carcinomas (HNSCC) and 4/6 (66.7%) anal cancers; EBV was detected in 8/129 (6.2%) HNSCC and 18/318 (5.7%) gastric cancers (GC). The dominant mutation signatures by disease included APOBEC for UC (135/236) and HNSCC (22/122), alcohol for HCC (19/35), HRD for OvCa (12/64) and triple-negative breast cancer (51/175), UV exposure for melanoma (145/176), and dMMR for GC (84/287) and CRPC (16/155). Samples with deleterious BRCA mutations showed significantly higher HRD-LOH score (N = 1420; AUROC = 0.61 [95% CI, 0.53-0.69]) and HRD mutational signature (N = 1316; DOR = 6.4 [95% CI, 3.7-11.1]). Conclusion We assembled heterogeneous computational modules into an integrated pipeline to reliably profile diverse molecular features from WES data of nearly 1500 clinical samples across different tumor types. These data serve as a foundation for translational research efforts supporting pembrolizumab development. Citation Format: Xiaoqiao Liu, Xinwei Sher, Hongchao Lu, Jun Zhuang, Weilong Zhao, Andrew Albright, Cinthia Umemoto, Christe","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133217307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 5104: Pan-cancer classification on gene expression data by neural network 5104:基于基因表达数据的泛癌分类
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-5104
Kijin Yu, Bong-Hyun Kim, P. C. Lee
{"title":"Abstract 5104: Pan-cancer classification on gene expression data by neural network","authors":"Kijin Yu, Bong-Hyun Kim, P. C. Lee","doi":"10.1158/1538-7445.SABCS18-5104","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-5104","url":null,"abstract":"Cancer classification based on molecular signatures such as gene expression profiles has been provided insights on causes of the disease or provided guidance for selecting patient’s treatment regimen. We developed a cancer classifier that can identify 13 different types of cancers or a normal tissue based on bulk RNA-seq data as well as single cell RNA-seq data. Training was performed with 6,483 samples from 13 cancer tissues and 640 samples from tumor-adjacent normal tissues in The Cancer Genome Atlas based on 300 most significant genes for the binary classification of each cancer. Then, we compared Neural network, Support vector machine, Naive Bayes and Random Forest methods. Neural network performed consistently better than other methods, even it took shorter time to train. We further applied our approach to bulked single cell data that is generated from single cell RNA-seq and found our model successfully classified cancer types and normal samples. Gene set enrichment analysis comparing cancer types found genes in cell cycle-related pathways, which highlights the differences between cancer types might be in their abilities to grow in different conditions. We also found genes that expressed in multiple cancers that can be novel biomarkers and therapeutic targets. Citation Format: Kijin Yu, Bong-Hyun Kim, Peter Chang Whan Lee. Pan-cancer classification on gene expression data by neural network [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5104.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133365475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract LB-210: An enhanced tumor evolution model for colorectal cancer evolution LB-210:结直肠癌进化的增强型肿瘤进化模型
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-LB-210
Lixing Yang
{"title":"Abstract LB-210: An enhanced tumor evolution model for colorectal cancer evolution","authors":"Lixing Yang","doi":"10.1158/1538-7445.AM2019-LB-210","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-LB-210","url":null,"abstract":"The classical genetic model of colorectal cancer presents somatic APC mutations as the earliest genomic alterations, followed by KRAS and TP53 mutations. However, the timing and relative order of clonal expansion and other types of somatic genome alterations such as genomic rearrangements are still unclear. Here, we performed detailed analysis of somatic genetic alterations, including point mutations, copy number alterations and genomic rearrangements, in 63 whole-genome sequenced colorectal cancers from the Cancer Genome Atlas Research Network. The relative order of these alterations occurring during tumorigenesis was inferred from variant allele fractions. We found that driver point mutations, gene fusions, and arm level copy losses typically arise early. Copy-neutral loss of heterozygosity is often a two-step event: a deletion followed by a duplication. Different mechanisms act in different genomic regions to optimize the DNA dosage. Chromothripsis, clustered genomic rearrangements previously thought to occur as a single catastrophic event, is frequent and may occur multiple times independently in the same tumor through different mechanisms. In contrast to recent studies reporting neutral growth of tumors, selection is often present on subclones. Our results suggest that different evolutionary models can operate in a single tumor at different stages. Combining these results, we present a refined tumor progression model for human colorectal cancer. Our enhanced genetic model significantly expands our understanding of tumorigenesis process. Citation Format: Lixing Yang. An enhanced tumor evolution model for colorectal cancer evolution [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-210.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133853182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 5098:In silicoanalysis of the membrane targeting mechanism of the pleckstrin homology domains within the oncogenic Grb2-associated-binding protein family 摘要:肿瘤grb2相关结合蛋白家族pleckstrin同源结构域的膜靶向机制的硅分析
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-5098
Antonio López, Ezza Awan, Areeba Zaheer, Shaneen Singh
{"title":"Abstract 5098:In silicoanalysis of the membrane targeting mechanism of the pleckstrin homology domains within the oncogenic Grb2-associated-binding protein family","authors":"Antonio López, Ezza Awan, Areeba Zaheer, Shaneen Singh","doi":"10.1158/1538-7445.AM2019-5098","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-5098","url":null,"abstract":"Members of the metazoan Grb2-associated-binding (GAB) family of proteins are crucial regulatory elements of receptor tyrosine kinase (RTK) signaling pathways. These scaffold proteins link and amplify plasma membrane receptor signaling to downstream targets by staging protein-protein interactions. Aberrant GAB expression is associated with improper growth and development, and several members of the GAB family have been implicated as oncogenes. GAB1, GAB2, and GAB3 are overexpressed in various cancers including lung, breast, colorectal, nervous system, and ovarian cancers, along with certain leukemias and melanomas. Recent studies suggest a direct relationship between GAB expression levels and tumorigenesis, where induced or silenced expression respectively accelerated or inhibited tumor proliferation. Silencing of GAB1 in colorectal cancers and GAB2 in glioblastoma via miRNA, and GAB3 in gliomas via siRNA inhibits tumor proliferation indicating that GAB proteins can be potentially effective targets in cancer therapy. The most conserved structural moiety in all members of the GAB family is an N-terminally located pleckstrin homology (PH domain) that directs subcellular localization and is crucial for effective protein function. Given the challenges facing RNA-based cancer therapies, more practical therapeutic avenues may be found in disrupting or inhibiting proper PH domain function; however, the mechanism of membrane targeting of all GABs remains to be elucidated. To this end, we have performed a comprehensive computational analysis of the six known GAB family members - chordate GAB1, GAB2, GAB3, and GAB4; Caenorhabditis elegans Suppressor of Clear (SOC1); Drosophila melanogaster Daughter of Sevenless (DOS) and their respective homologs to establish intra-familiar relationships via sequence analysis. Furthermore, in silico homology-based and ab initio modeling techniques were employed to propose suitable structural models of the PH domains and confirm the structural conservation of the fold. The refined theoretical models were docked against phosphoinositide head-groups to establish binding affinities and the mechanism of GAB PH domain localization. Our results suggest that non-specific electrostatics may be a key component for membrane targeting of GAB PH domains acting in concert with interaction through specific conserved residues and reveal an alternative binding pocket in addition to the canonical binding site. Our study is the first step in rational design of potential therapies based on targeting GAB function via the PH domain. Citation Format: Antonio Lopez, Ezza Awan, Areeba Zaheer, Shaneen Singh. In silico analysis of the membrane targeting mechanism of the pleckstrin homology domains within the oncogenic Grb2-associated-binding protein family [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 50","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133352570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 1674: Prediction of survival based on tumor size dynamics and new lesions in EGFR mutation-positive non-small cell lung cancer patients treated with gefitinib or carboplatin and paclitaxel [摘要]基于肿瘤大小动态和新病变的EGFR突变阳性非小细胞肺癌患者接受吉非替尼或卡铂和紫杉醇治疗的生存预测
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-1674
J. Dunyak, Jacqueline Buros-Novik, E. Novik, Hong-Hong Yan, N. Al-Huniti
{"title":"Abstract 1674: Prediction of survival based on tumor size dynamics and new lesions in EGFR mutation-positive non-small cell lung cancer patients treated with gefitinib or carboplatin and paclitaxel","authors":"J. Dunyak, Jacqueline Buros-Novik, E. Novik, Hong-Hong Yan, N. Al-Huniti","doi":"10.1158/1538-7445.SABCS18-1674","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1674","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122257599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 1679: Neoepitope screening in colorectal cancer patients by custom exome panel profiling somatic mutations 1679:通过定制外显子组面板分析体细胞突变来筛选结直肠癌患者的新表位
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-1679
Raghavee Venkatramanan, K. Deutsch, Inah Golez, Pallavi Shroff, Spencer L Seale, Brendan Ralph, Sally Dow, Evan Anderson, Saman Tahir, Anjali Malge, C. Braastad, S. Anderson
{"title":"Abstract 1679: Neoepitope screening in colorectal cancer patients by custom exome panel profiling somatic mutations","authors":"Raghavee Venkatramanan, K. Deutsch, Inah Golez, Pallavi Shroff, Spencer L Seale, Brendan Ralph, Sally Dow, Evan Anderson, Saman Tahir, Anjali Malge, C. Braastad, S. Anderson","doi":"10.1158/1538-7445.SABCS18-1679","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1679","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115346423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 4236: Evaluating alterations in mRNA biogenesis with TCGA breast cancer sequencing data 4236:利用TCGA乳腺癌测序数据评估mRNA生物发生的变化
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-4236
Thomas J. Yan, M. Burow, E. Martin
{"title":"Abstract 4236: Evaluating alterations in mRNA biogenesis with TCGA breast cancer sequencing data","authors":"Thomas J. Yan, M. Burow, E. Martin","doi":"10.1158/1538-7445.SABCS18-4236","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-4236","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"130 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115917493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 3372: Cell-free DNA (cfDNA) fragment length patterns of tumor- and blood-derived variants in participants with and without cancer 摘要3372:肿瘤和血液来源变异的无细胞DNA (cfDNA)片段长度模式在患有和没有癌症的参与者中
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-3372
E. Hubbell, T. Maddala, Oliver Venn, Eric Scott, Susan Tang, Archana Shenoy, A. Aravanis
{"title":"Abstract 3372: Cell-free DNA (cfDNA) fragment length patterns of tumor- and blood-derived variants in participants with and without cancer","authors":"E. Hubbell, T. Maddala, Oliver Venn, Eric Scott, Susan Tang, Archana Shenoy, A. Aravanis","doi":"10.1158/1538-7445.AM2019-3372","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-3372","url":null,"abstract":"Previous studies on transplanted tissue or single cancers indicated that cfDNA variant fragment lengths reflect their respective source. The Circulating Cell-free Genome Atlas (NCT02889978) study provides an opportunity to examine cfDNA variant fragment lengths across tumor types and describe the nature of cfDNA variants derived from different sources. Blood samples (N=1406) were evaluated from participants with (n=845) and without (n=561) cancer; cancer samples included 339 breast, 118 lung, 69 prostate, 45 colorectal, 27 uterine, 26 pancreas, 26 renal, 24 esophageal, 22 lymphoma, 19 head/neck, and 17 ovarian (113 remaining samples represented cancers with ≤15 samples each). cfDNA and genomic DNA from white blood cells (WBC) were subjected to a high-intensity targeted panel (507 genes, 60000X) with error-corrected sequencing; 533 samples also had matched tumor biopsy tissue subjected to whole-genome sequencing (30X). Somatic single-nucleotide variants (SNVs; that passed noise filters) were identified and classified using the sequencing results into one of four categories: tumor biopsy-matched (TBM; present in cfDNA and biopsy), WBC-matched (WM; present in cfDNA and WBC), non-matched (NM; low probability [P A total of 21604 SNVs were identified. The proportion of SNVs from each category were: 4% TBM, 68% WM, 19% NM, and 8% AMB. The number of samples (non-mutually exclusive) that had each SNV category were 152 TBM, 1338 WM, 499 NM, and 761 AMB. Across categories, the median (SD) length of fragments containing the reference allele was 167 (16.3). Median (SD) fragment lengths of TBM, WM, NM, and AMB were 156 (22.2), 169 (14.8), 158 (20.8), and 165 (17.8), respectively. AMB and WM median SNV fragment lengths were similar to that of the reference allele, suggesting that fragment length shifts are minimal in SNVs derived from clonal hematopoiesis (CH). Fragment lengths of TBM and NM SNVs were similar; further, most NM SNVs came from cfDNA samples in the cancer cohort, suggesting that NM SNVs may be tumor-derived. As expected in a population with a median (SD) age of 61 (12.2), most SNVs occurred in the WM category. The prediction model distinguished TBM from WM SNVs with an AUC of 0.87. However, at a specificity of 98% (to match filtering based on WBC sequencing), false-negative rates were 35% (TBM) and 52% (NM). Together, these data suggest that source prediction based on fragment length alone is less robust than source assignment using individual-matched WBC sequencing, highlighting the importance of accounting for CH-derived SNVs when using targeted cfDNA-based approaches for cancer detection. Citation Format: Earl Hubbell, Tara Maddala, Oliver Venn, Eric Scott, Susan Tang, Archana Shenoy, Alex Aravanis. Cell-free DNA (cfDNA) fragment length patterns of tumor- and blood-derived variants in participants with and without cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, ","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123669222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Abstract 1663: Analytical methods to identify tumor heterogeneity and rare subclones in single cell DNA sequencing data from targeted panels 1663:鉴定肿瘤异质性和罕见亚克隆的单细胞DNA测序数据分析方法
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-1663
M. Manivannan, Sombeet Sahu, Shu Wang, Dong Kim, Niranjan Vissa, Jordan Wilheim, A. Sciambi, Nianzhen Li, Robert Durruthy-Durruthy, Anup Y. Parikh, K. Jones
{"title":"Abstract 1663: Analytical methods to identify tumor heterogeneity and rare subclones in single cell DNA sequencing data from targeted panels","authors":"M. Manivannan, Sombeet Sahu, Shu Wang, Dong Kim, Niranjan Vissa, Jordan Wilheim, A. Sciambi, Nianzhen Li, Robert Durruthy-Durruthy, Anup Y. Parikh, K. Jones","doi":"10.1158/1538-7445.AM2019-1663","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-1663","url":null,"abstract":"Current bulk sequencing paradigms are inadequate to characterize complicated biological systems where somatic variation is buried in the landscape of populations. Single-cell DNA sequencing can simultaneously identify zygosity, rare alleles and determine whether mutations co-occur within the same cell. While high-throughput single-cell DNA analysis has been a recent innovation, it is essential to develop new capabilities for assessing genetic variation present in rare cells and to better understand the role that these cells play in the evolution of tumor progression. To address these challenges and enable the characterization of genetic diversity in cancer cell populations, we developed analytical methods to identify mutation signatures which define subclones present in a tumor population. Here we present a workflow for subclone identification using data generated on the Tapestri single-cell DNA platform. The analytical pipeline steps include obtaining raw reads from the sequencer, removing adapters, aligning and mapping the reads, calling individual cells, error correction of reads assigned to cells and identifying genetic variants within each cell. After filtering for high quality variants, we then filter for data completeness to ensure high quality data is used in downstream processing. The variant-cell matrix is then subjected to clustering to identify subclones. Top variants that define the signature of each subclone are also identified. To validate our methodology, we used data from two different targeted panels on different model systems with known truth mutations. Our pipeline shows the distinct clusters correlating with titration and cell line ratios. Cluster associated signature mutations were also identified. The pipeline can be used for multi sample analysis with time-series data from diagnosis to relapse or from primary site to metastasis to understand clonal diversity. These data demonstrate the utility of the Tapestri platform, the analytical pipeline, and associated data visualization capability. Our approach addresses key issues of identifying rare subpopulations of cells down to 0.1%, and transforms the ability to accurately characterize clonal heterogeneity in tumor samples. This high throughput method advances research efforts to improve patient stratification and therapy selection for various cancer indications. Citation Format: Manimozhi Manivannan, Sombeet Sahu, Shu Wang, Dong Kim, Niranjan Vissa, Jordan Wilheim, Adam Sciambi, Nianzhen Li, Robert Durruthy-Durruthy, Anup Parikh, Keith Jones. Analytical methods to identify tumor heterogeneity and rare subclones in single cell DNA sequencing data from targeted panels [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1663.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"117 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124431259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 2438: Rapid fluorescence based assessment of RNA integrity quality using machine learning 2438:基于机器学习的RNA完整性质量快速荧光评估
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-2438
Scott T. Clarke, D. Poulsen, Chris L Vonnegut, Debra K. Gale, Kathy Free
{"title":"Abstract 2438: Rapid fluorescence based assessment of RNA integrity quality using machine learning","authors":"Scott T. Clarke, D. Poulsen, Chris L Vonnegut, Debra K. Gale, Kathy Free","doi":"10.1158/1538-7445.AM2019-2438","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-2438","url":null,"abstract":"Much attention has been focused on RNA transcript bias. The quality of isolated mRNA used for RNA-seq and other downstream analyses can contribute to sample specific bias of transcript abundance. If the library is prepared from polyA enrichment of degraded RNA or with reverse transcriptase using oligo dT priming then 3′ positional bias must be considered (Irizarry 2016). Isolated total RNA is routinely examined for its quality prior to committing to costly gene expression analysis. Since total RNA consists of ~85% rRNA, analysis primarily reflects rRNA quality and the mRNA quality is inferred. Typically, measurements consist of 260/280 nm ratio, 28S/18S rRNA ratio and capillary electrophoresis fragment analysis or gel-based separation and imaging methods. These methods which have become industry standards of quality generate an RNA score such as RNA integrity number (RIN) between 0-10 with >8 being acceptable for RNA-seq. Generating RIN score requires experienced technical ability, specialized equipment, as well as additional cost and time prior to committing to the next step of building the library for sequencing. In this presentation we examine the integrity of the RNA using a combination of nucleic acid specific fluorescent dyes which display different binding specificity depending on the primary and secondary structure of the RNA. Fluorescence signal is analyzed using machine learning based algorithm. For machine learning, a training data set of data was generated, followed by a test set of data used to determine accuracy. Data depicting the actual vs. predicted class are reported in a confusion matrix. Variable of importance analysis was used to determine the factors most important for predicting accurate RNA integrity quality (IQ). With machine learning the initial determination of accuracy using the test data, ranged between 92.7 - 95.7% over the entire range depending on the algorithm. With further refinement of the machine learning approach, RNA IQ had an accuracy of ±0.65 and ± 0.39 standard deviation (SD) for IQ range 0 - 10 using the test data set. The accurate and low SD generated using nucleic acid binding dyes makes for a quick, simple and easy to use assessment of isolated RNA. The dye binding and fluorescent measurement is rapid and requires only a few minutes to generate. Comparison of the dye/RNA based fluorescence based determination of RNA IQ was benchmarked against the industry standards using the BioAnalyzer system (Agilent) to generate a RIN score and other gel analysis methods to determine concordance and utility of this method. Technical ability, cost and time investment are minimal allowing for rapid sample characterization prior to further analysis and commitment to downstream sequencing steps. Citation Format: Scott T. Clarke, Dylan Poulsen, Chris Vonnegut, Debra Gale, Kathy Free. Rapid fluorescence based assessment of RNA integrity quality using machine learning [abstract]. In: Proceedings of the American Association","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"410 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114550461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书